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Allelic Variations of the Multidrug Resistance Gene Determine
Susceptibility and Disease Behavior in Ulcerative Colitis
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CRAIG MOWAT,* IAN D. ARNOTT,* and JACK SATSANGI*
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Background & Aims: The MDR1 gene encodes P-glyco-
protein 170, an efﬂux transporter that is highly ex-
pressed in intestinal epithelial cells. The MDR1 exonic
single nucleotide polymorphisms (SNPs) C3435T and
G2677T have been shown to correlate with activity/
expression of P-glycoprotein 170. Methods: This was a
case-control analysis of MDR1 C3435T and G2677T
SNPs in a large well-characterized Scottish white cohort
(335 with ulcerative colitis [UC], 268 with Crohn’s dis-
ease [CD], and 370 healthy controls). We conducted
2-locus haplotype and detailed univariate and multivar-
iate genotypic-phenotypic analyses. Results: The MDR1
3435 TT genotype (34.6% vs 26.5%; P  .04; odds ratio
[OR], 1.60; 95% conﬁdence interval [95% CI], 1.04–
2.44) and T-allelic frequencies (58.2% vs 52.8%; P 
.02; OR, 1.28; 95% CI, 1.03–1.58) were signiﬁcantly
higher in patients with UC compared with controls. No
association was seen with CD. The association was
strongest with extensive UC (TT genotype: 42.4% vs
26.5%; P  .003; OR, 2.64; 95% CI, 1.34–4.99; and T
allele: 63.9% vs 52.8%; P  .009; OR, 1.70; 95% CI,
1.24–2.29), and this was also conﬁrmed on multivariate
analysis (P  .007). The G2677T SNP was not associ-
ated with UC or CD. These 2 SNPs lie in linkage disequi-
librium in our population (D=, .8–.9; r2, .7–.8). Two-locus
haplotypes showed both positive (3435T/G2677 haplo-
type: P  .03; OR, 1.44) and negative (C3435/2677T
haplotype: P  .002; OR, .35) associations with UC.
Homozygotes for the haplotype 3435T/G2677 were sig-
niﬁcantly increased in UC (P  .017; OR, 8.88; 95% CI,
1.10–71.45). Conclusions: Allelic variations of the
MDR1 gene determine disease extent as well as suscep-
tibility to UC in the Scottish population. The present data
strongly implicate the C3435T SNP, although the 2-locus
haplotype data underline the need for further detailed
haplotypic studies.
Ulcerative colitis (UC) and Crohn’s disease (CD) arecommon, chronic inflammatory disorders of the
intestines characterized by a dysregulated mucosal im-
mune response.1 Epidemiologic and linkage studies sug-
gest that genetic factors play a significant role in deter-
mining susceptibility to inflammatory bowel disease
(IBD).2 Genetic linkage analyses, through genome-wide
screens, have identified a number of susceptibility loci,
revealing the complexity of IBD.
Recent attention has focused on the multidrug resis-
tance 1 (MDR1) gene and its product, P-glycoprotein
170, as a potential determinant of susceptibility to IBD.3
P-glycoprotein 170, which functions as an adenosine
triphosphate–dependent efflux transporter pump, is
highly expressed in the epithelial surfaces of the intes-
tine, biliary ductules, proximal tubules of kidneys, and
central nervous system, where it forms the basis of the
blood-brain barrier.4–6 Interindividual variability of P-
glycoprotein expression in the intestine plays a role in
determining the pharmacokinetics of a wide-ranging
number of substrates. Nevertheless, the exact physiologic
role in the gut remains unknown. The high constitutive
levels of expression of P-glycoprotein 170 in the gut
suggest a role in protection not only against xenobiotics
but also bacterial products.
The MDR1 gene is an attractive candidate gene for
IBD for several reasons.3 First, mdr-1a–deficient mice
develop a UC-like phenotype when maintained in a
specific pathogen–free environment that is reversed with
antibiotics.7 Bone marrow transfer studies show that
these mice develop colitis primarily due to deficiency of
mdr-1 in the epithelial rather than the lymphoid cells.
Second, the MDR1 gene maps to chromosome 7q22,
which has been identified as a putative locus of suscep-
tibility for IBD by genome-wide scanning in a UK
cohort.8 Recent subsequent meta-analysis of all genome-
wide scans confirms suggestive linkage to this region.9
Most recently, compelling data by Langmann et al have
shown that MDR1 gene expression is down-regulated in
IBD with expression significantly reduced in the colonic
tissue of patients with UC but not CD.10 In contrast to
Abbreviations used in this paper: CI, conﬁdence interval; OR, odds
ratio; SNP, single nucleotide polymorphism.
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this, Farrell et al have suggested that increased P-glyco-
protein 170 expression may be associated with failure of
medical therapy in IBD.11
The MDR1 gene is composed of 28 exons and is
209 kilobases in length, and 29 single nucleotide poly-
morphisms (SNPs) have been described.12–14 Two SNPs,
exonic variant C3435T and G2677T/A, have been shown
to correlate with activity/expression of P-glycoprotein
170. The C3435T SNP in exon 26 has been most exten-
sively investigated and was first shown to correlate with
expression of P-glycoprotein 170.12 In this study, the TT
genotype was associated with decreased intestinal P-
glycoprotein 170 expression with functional consequence
as inferred by increased digoxin uptake following oral
administration.15 This has been replicated in other phar-
macokinetic studies.16–18 In addition, the effect of the
MDR1 C3435T SNP and its postulated correlation with
P-glycoprotein 170 activity/expression has been shown
to play a role in drug-resistant epilepsy,19 immune re-
covery after initiation of antiretroviral therapy in human
immunodeficiency virus,20 and the development of renal
cell carcinoma.21
The G2677T/A SNP in exon 21 results in 2 distinct
amino acid changes, namely 893Ser (G2677T) or the much
rarer 893Thr (G2677A), and has been shown to be associ-
ated with altered transporter function or expression.17,22
Several studies have suggested that the C3435T and
G2677T SNP may lie in linkage disequilibrium.17,23–25
Recently, Schwab et al in Germany suggested that
both T allele and TT genotype were associated with
increased susceptibility in UC but not CD.26 Subsequent
replication studies involving this SNP alone in other
centers have been inconsistent.27,28 In a North American
study examining both G2677T and C3435T SNPs (and,
additionally, a C1236T variant in exon 12), Brant et al29
showed an association only between the Ala893 poly-
morphism (G2677) and IBD, although these investiga-
tors did not specify whether the association was with CD
or UC. A significant association was observed from both
a case-control study and a pedigree disequilibrium test
with IBD. The investigators proposed that the G allele
(Ala893) might confer a genetic risk factor to suscepti-
bility of IBD.
We aimed firstly to investigate the contribution of the
MDR1 C3435T and G2677T SNP in a large, indepen-
dent, well-characterized population of Scottish white
people. We determined whether 2-locus haplotypes pro-
vide a stronger association with disease than individual
SNPs to resolve the controversies regarding the contri-
bution of this gene to disease susceptibility. We rigor-
ously conducted a detailed subphenotypic review of all
subjects genotyped to assess whether these variants are
particularly implicated in determining disease extent and
behavior in IBD. To clarify whether MDR1 genotypes
may influence drug responsiveness in UC, we further
subcategorized our patients to the phenotypes of severe
disease and need for surgery in UC.
Patients and Methods
Patients
This study was approved by the Lothian Research and
Ethics Committee, and written consent was obtained from all
patients. A total of 335 patients with UC and 268 with CD
were recruited from the Lothian region (Scotland). The diag-
nosis of IBD was determined by standard clinical, radiologic,
endoscopic, and histologic criteria.
Tables 1 and 2 summarize the clinical characteristics of
patients studied. The median ages at diagnosis of UC and CD
were 35.0 years (interquartile range, 25.3–50.3 years) and 26.6
years (interquartile range, 19.9–37.0 years), respectively. The
ethnicity of our study population was predominantly Scottish
white (99%). There were more men in the UC cohort (54.5%)
than in the CD cohort (43.5%).
Phenotypic Assessment
UC phenotype was classified by disease extent, disease
severity, and need for surgery. The extent of disease was
documented at the time of latest follow-up. We defined ex-
tensive disease as disease extending beyond the splenic flexure,
left-sided colitis as disease extending to the splenic flexure, and
proctitis as disease limited to the rectum as determined by
histologic and macroscopic evidence. In discordant cases, the
histologic evidence was used. Patients who had developed an
Table 1. Demographics and Clinical Characteristics of
Patients With UC (n  335)
Sex (M/F) 184/151
Age at onset (y) 35.0 (25.3–50.3)
Age at onset younger than 16 years (%) 10 (3)
Smoking history (%)
Current 28 (8.5)
Ex-smoker 135 (40.4)
Never 172 (51.4)
Ethnicity
Scottish white (%) 99
Other 1 Jewish, 1 Japanese, and
2 Asian persons
Disease extent
Extensive disease (beyond the
splenic flexure) 118 (35.2)
Left-sided colitis 149 (44.5)
Proctitis 68 (20.3)
Severe diseasea 113 (33.7)
Surgery for severe disease 63 (18.8)
Extraintestinal manifestations (%) 31 (9.4)
Primary sclerosing cholangitis (%) 6 (1.8)
Azathioprine therapy (%) 48 (14.2)
aSevere UC defined as patients who developed a severe acute attack
of UC satisfying the Truelove and Witts criteria.
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acute severe attack of UC (satisfying the Truelove and Witts
criteria) requiring intensive inpatient medical therapy were
regarded to have severe UC. Within the category of severe UC,
a further subset of patients who had failed to respond to
medical therapy and consequently required surgery were cat-
egorized under the phenotype “need for surgery.” Other phe-
notypic details such as smoking, family history, presence of
primary sclerosing cholangitis, and other extraintestinal man-
ifestations were also recorded.
CD was classified according to the Vienna classification of
disease location, behavior, and age at diagnosis as previously
described.30 We have previously shown that disease behavior is
not stable over time and therefore have analyzed disease be-
havior only at time of diagnosis and at latest follow-up.31
Controls
A total of 370 healthy controls, comprised of actively
recruited healthy subjects (n  105) and blood donors (n 
265), were all recruited from the Lothian region between 2000
and 2002. There were no differences in the demographics
between these 2 groups. There were 179 men and 191 women,
and the median age at recruitment was 37.1 years (interquar-
tile range, 25.9–47.0 years).
Genotyping
Genotyping was performed using TaqMan (ABI, San
Diego, CA). TaqMan probes were available from ABI-assay-
on-demand/design: C3435T (rs1045642) and G2677T/A
(rs2032582). Sequence and reaction settings are available on
request.
G2677T/A is a triallelic SNP, with reported frequencies of
the rare A allele in European white people ranging from
undetected to 4%.13,17,32–34 We sequenced 200 chromosomes
of the UC group (100 individuals) and confirmed a G2677A
allelic frequency of only 2% in our population. In view of this
low frequency, we chose to genotype the 2 common variants of
the G2677T/A SNP using TaqMan reaction.
Data Analysis
Genotype and allelic frequencies between cases and
controls were compared using a 2  2 table and Fisher exact
test. Odds ratios (ORs) are given with 95% confidence inter-
vals (CIs) and 2-sided P values. P  .05 was considered
significant. All calculations were performed using the Graph
Pad Instat program (Graph Pad Software, San Diego, CA).
Fisher exact test was used to evaluate if the homozygote and
heterozygote frequencies for each SNP deviate from the Har-
dy–Weinberg equilibrium. Two-locus haplotype frequencies
were measured using the expectation-maximization algorithm
utilizing the SNPHAP program (bioinformatic programs
available and accessed via the Medical Research Council–
Rosalind Franklind Centre of Genomic Research Web site:
http://www.rfcgr.mrc.ac.uk).35
Multivariate analysis was performed using a logistic regres-
sion model to test the association between phenotype and
genotypes. Two methods were used for haplotypic association
with disease: (1) the log-likelihood ratio method, in which
inferred haplotypes were compared in cases, controls, and
cases/controls combined, and (2) directly comparing the hap-
lotype frequencies between cases and controls. The log-likeli-
hood ratio tests whether a model in which haplotype frequen-
cies in cases are different from controls or a model in which
there are no differences between cases and controls fit the data
obtained better.35 Significance for association was calculated
using the test statistic 2*ln(Lcase)  ln(Lcontrol)  ln(Lcase/
Lcontrol), which has a 2 distribution with n  1 df, where n
is the number of inferred haplotypes. We measured the linkage
disequilibrium between SNPs using Cocaphase software
(bioinformatic programs available and accessed via the Medical
Research Council–Rosalind Franklind Centre of Genomic Re-
search Web site: http://www.rfcgr.mrc.ac.uk).
The log-likelihood analysis and direct haplotype comparison
are complementary methods to detect association in haplotypic
data sets. Log-likelihood analysis is used specifically to address
the problem of phase uncertainty encountered when direct
comparisons are made from haplotype frequencies that are
inferred. Direct haplotype comparison assumes that all haplo-
types are known without error and therefore can be counted.
However, there remains a degree of uncertainty even in the
Table 2. Demographics and Clinical Characteristics of
Patients With CD
Sex (M/F) 117/151
Smoking history (%)
Current 68 (25.4)
Ex-smoker 77 (28.7)
Never 123 (45.9)
Age at onset (y) 26.6
Median (interquartile range) (19.9–37.0)
Age at onset 203
No. (%) (younger than 40 years, A1) (75.7)
Ethnicity
Scottish white (%) 99
Other (1 Jewish and 2
Asian persons)
Drug therapy (%)
Infliximab 45 (16.8)
Azathioprine 106 (39.5)
Disease location (%) (n  240)
Ileal (L1) 83 (30.9)
Colonic (L2) 118 (39.9)
Ileocolonic (L3) 57 (21.3)
Upper gastrointestinal (L4) 21 (7.9)
Disease behavior at diagnosis (%)
Inflammatory (B1) 196 (73.1)
Stricturing (B2) 21 (7.8)
Penetrating (B3) 51 (19.0)
Disease behavior at latest follow-up (%)
Inflammatory (B1) 95 (35.4)
Stricturing (B2) 43 (16.1)
Penetrating (B3) 130 (48.4)
Surgery (%) 122 (45.8)
Extraintestinal manifestations (%) 59 (22.1)
NOTE. Disease location, behavior, and age at onset were defined
according to the Vienna classification.
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case of estimated diplotypes. Although the likelihood-based
method will test for association, it does not provide an estimate
of the size of the effect; for this, we used the diplotypes most
likely to do so.
Results
Effect of MDR1 C3435T and G2677T
Polymorphism on Overall Disease
Susceptibility
Both the T allele and TT genotype of the MDR1
3435 SNP were significantly increased in patients with UC
(58.2% vs 52.8%; P .02; OR, 1.28; 95% CI, 1.03–1.58)
compared with healthy controls (34.6% vs 26.5%; P .04;
OR, 1.60; 95% CI, 1.04–2.44) (Table 3). No significant
differences in allele or genotype frequencies were seen in
patients with CD (53.0% vs 52.8% [P  .43] and 26.9%
vs 26.5% [P  .81], respectively) when compared with
controls. A trend toward higher T-allele and genotype
frequencies in UC was observed when compared with CD
(58.2% vs 53.0% [P  .12] and 34.6% vs 26.9% [P 
.07]).
We did not detect any significant differences in car-
riage rate (presence of one or 2 copies of alleles) of 3435T
in the 3 groups (UC, 81.8%; CD, 79.1%; healthy con-
trols, 77.8%). Our data suggest that the TT genotype
rather than T-allele carriage plays the more significant
role in the association with UC. The OR, compared with
the CC genotype, for the TT genotype was 1.59 (95%
CI, 1.04–2.44) and for the CT genotype was 1.12 (95%
CI, .76–1.66). Therefore, a stronger significance was also
obtained when we compared the homozygosity rate (TT
genotype/non-TT genotype) in UC (P  .02; OR, 1.47;
95% CI, 1.06–2.03).
No significant differences were observed for allelic and
genotype frequencies for MDR1 G2677T polymorphism
on overall disease susceptibility for either UC or CD
(Table 4). There was no overall association with IBD in
our population for the G2677T SNP (P .26), although
the G2677 allele frequency showed a trend to be higher
in patients with UC compared with controls (54.6% and
51.2%, respectively). All genotype frequencies in both
cases and controls were consistent with Hardy–Weinberg
equilibrium.
In addition to this, we performed a sex-matched anal-
ysis for both C3435T and G2677T SNP with controls
(335 and 268 healthy controls with 48.5% and 43.5%
men for UC and CD, respectively). The association ob-
served with C3435T SNP and UC remained significant,
with the TT genotype (P  .05; OR, 1.58; 95% CI,
1.02–2.45) and T allele (P  .03; OR, 1.26; 95% CI,
1.03–1.06) both significantly increased. No other signif-
icant differences were detected in sex-matched analysis
(full details available on request).
Linkage Disequilibrium Between C3435T
and G2677T Polymorphisms
The C3435T and G2677T SNP are in linkage
disequilibrium with each other in our population (cases,
D=  .8 and r2  .7; controls, D=  .9 and r2  .8).
Therefore, we proceeded to perform 2-locus haplotype
association tests with UC and CD.
The Effect of 2-Locus Haplotype (C3435T/
G2677T) on Disease Susceptibility
Using the log-likelihood ratio test as described
earlier, we were able to show an association of 2-locus
haplotypes of C3435T/G2677T with UC (P  .0056, 3
df ). On single haplotype analysis, the carriage of 3435T/
2677G haplotype conferred an increased risk for UC
(OR, 1.44; P  .03; 95% CI, 1.03–1.99) (Table 5). In
Table 3. Genotype and Allelic Frequencies of MDR1 C3435T Polymorphism in UC and CD Compared With Controls
CC (%) CT (%) TT (%) C (%) T (%) TT vs CC/OR/95% CI T vs C/OR/95% CI
UC (n  335) 61 (18.2) 158 (47.2) 116 (34.6) 280 (41.8) 390 (58.2) .04/1.60/1.04–2.44 .02/1.28/1.03–1.58
CD (n  268) 56 (20.9) 140 (52.2) 72 (26.9) 252 (47.0) 284 (53.0) .81/1.08/.68–1.69 .43/1.03/.83–1.29
Healthy controls
(n  370) 82 (22.2) 190 (51.3) 98 (26.5) 354 (47.8) 386 (52.8)
NOTE. UC vs CD: TT genotype, P  .12; OR, 1.48; 95% CI, .93– 2.36; T allele, P  .07; OR, 1.24; 95% CI, .98–1.24.
Table 4. Genotype and Allele Frequencies of MDR1 G2677T Polymorphism in UC and CD Compared With Controls
GG (%) GT (%) TT (%) G (%) T (%) GG vs TT/OR/95% CI G vs T/OR/95% CI
UC (n  335) 95 (28.3) 176 (52.5) 64 (19.1) 366 (54.6) 304 (45.4) .16/1.37/.89–2.09 .19/1.15/.93–1.42
CD (n  268) 75 (27.9) 133 (47.8) 60 (22.4) 283 (52.8) 253 (47.2) .57/1.15/.74–1.79 .57/1.07/.86–1.34
Healthy controls
(n  370) 102 (27.6) 174 (47.0) 94 (25.4) 378 (51.2) 362 (49.8)
NOTE. UC vs CD: GG genotype, P  .48; OR, 1.19; 95% CI, .75– 1.89; G allele, P  .19; OR, 1.15; 95% CI, .93–1.89.
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contrast, carriage of the 3435C/2677T haplotype was
associated with a protective effect in UC (OR, .35; P 
.002; 95% CI, .17–.69). Similar trends were observed
with the same haplotypes in CD, but these failed to reach
significance (3435C/2677T allele, P  .20; 3435T/
2677G allele, P  .13).
It is noteworthy that a significantly higher number of
patients with UC were homozygotes for both TT 3435
and GG 2677 compared with a low frequency in healthy
controls (8 patients possessing 3435TT and GG 2677
genotype vs 1; P  .017; OR, 8.88; 95% CI, 1.10–
71.45). A similar trend was observed in patients with CD
(5 patients possessing 3435TT and GG 2677 genotype;
P  .08; OR, 6.82; 95% CI, .79–58.77). Combining
UC and CD yielded a greater significance (P  .013;
OR, 8.34; 95% CI, 1.09–64.07). There were no obvious
associations observed in simple and compound heterozy-
gotes of either UC or CD with healthy controls.
Because carriers of double homozygote mutants
were uncommon (14 individuals in total), we analyzed
the phenotypes of these patients. In UC, 6 of 8 pa-
tients had pancolitis, of whom 4 required surgery as a
consequence of severe disease. Of the 5 patients with
CD carrying these 2 mutations, one patient had co-
lonic disease (L2), 3 had ileocolonic disease (L3), and
one had ileal disease (L1); 3 of 5 of these patients
required surgery for active disease.
Genotype-Phenotype Analysis: Univariate
Analysis
UC and CD. The T allele and TT genotype of the
MDR1 C3435T showed a highly significant association
with the phenotype of extensive disease (OR, 1.70; 95% CI,
1.24–2.29; P  .009 and OR, 2.64; 95% CI, 1.34–4.99;
P  .0027, respectively). Both the frequencies of T allele
and TT genotype of MDR1 C3435T were increased in
patients with left-sided colitis and proctitis, but these dif-
ferences were not significant. A significantly higher T-allele
frequency was also observed in patients with severe disease
(OR, 1.39; P  .04; 95% CI, 1.02–1.88). Although the
T-allele and TT-genotype frequencies were even higher in
the subgroup of patients who had required surgery for
failure of medical treatment for severe UC (T-allele fre-
quency, 60.3%; TT genotype, 41.3%), significance was not
achieved in this smaller group (Table 6).
Interestingly, for the MDR1 G2677T SNP, trends of
association to severe disease and surgery were observed for
the GG genotype and G allele. In patients with severe
disease who required surgery, the GG-genotype frequency
was 41.2% compared with 27.5% of controls
(P .11; OR, 1.85; 95% CI, .89–3.85). This trend was not
observed in the subgroup of patients with extensive disease.
We did not observe any associations with subpheno-
typic categories of CD (data not shown); specifically,
colonic CD was not associated with either SNP (24.7%
TT-genotype frequency vs 26.5% for controls; P  .9).
Multivariate Analysis
The phenotypes of disease extent, disease severity,
and need for surgery were considered in our multivariate
model. Multivariate analyses show that the TT genotype
of MDR1 3435 remained significantly associated with
extensive disease (P  .007). The phenotypes of severe
disease and surgery were not significant (P .8 and P
Table 5. Two-Locus Haplotypes of C3435T/G2677T SNPs With UC and CD
Haplotype UC (%)
Healthy
Controls (%) P value/OR/95% CI CD (%)
Healthy
Controls (%) P value/OR/95% CI
3435T/2677T 291/379 (43.4) 332/408 (44.9) .59/.94/.76–1.16 219/317 (40.8) 332/408 (44.9) .16/.85/.67–1.06
C3435/G2677 276/394 (41.2) 300/440 (40.6) .82/1.03/.83–1.27 221/315 (41.2) 300/440 (40.6) .82/1.03/.82–1.29
3435T/G2677 91/579 (13.5) 73/667 (9.8) .03/1.44/1.03–1.99 65/471 (12.1) 73/667 (9.8) .20/1.26/.88–1.79
C3435/2677T 11/659 (1.7) 34/706 (4.6) .002/.35/.17–.69 35/501 (5.9) 34/706 (4.6) .13/1.45/.89–2.36
NOTE. Contingency tests were used to test the association of the inferred haplotypes in the groups of UC and CD, respectively, as compared with
the control group (total number of a particular haplotype/total number of remaining haplotypes compared between cases and controls with P
values and 95% CIs given).
Table 6. Genotype-Phenotype Analysis for C3435T and G2677T SNP in UC
C3435T G2677T
Genotypes CC (%) CT (%) TT (%)
TT genotype:
P value/OR/95% CI
T-allele frequency:
P value/OR/95% CI GG (%) GT (%) TT (%)
GG genotype:
P value/OR/95% CI
G-allele frequency:
P value/OR/95% CI
Extensive UC 17 (14.4) 51 (43.2) 50 (42.4) .003/2.64/1.34–4.99 .009/1.70/1.24–2.29 32 (27.1) 60 (50.9) 26 (22.0) .76/1.13/.63–2.04 .71/1.06/.79–1.42
Left-sided disease 30 (20.1) 74 (49.7) 45 (30.2) .49/1.25/.73–2.17 .41/1.12/.86–1.47 44 (29.5) 80 (53.7) 25 (16.8) .12/1.62/.92–2.85 .13/1.24/.94–1.62
Proctitis 14 (20.6) 37 (54.4) 21 (30.9) .58/1.25/.60–2.62 .57/1.11/.79–1.59 19 (27.9) 36 (52.9) 13 (19.1) .57/1.35/.63–2.88 .51/1.14/.79–1.65
Severe disease 23 (20.3) 44 (38.9) 46 (40.7) .09/1.67/.94–2.99 .04/1.39/1.02–1.88 35 (31.0) 53 (47.8) 20 (21.2) .17/1.61/.87–2.99 .14/1.27/.93–1.72
Surgery for severe
disease 13 (20.6) 24 (38.1) 26 (41.3) .21/1.67/.81–3.46 .18/1.31/.89–1.91 26 (41.2) 24 (38.1) 13 (20.6) .11/1.84/.89–3.79 .06/1.46/.99–2.14
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.4, respectively). Other models, which included age at
onset, smoking status, presence of primary sclerosing
cholangitis, and extraintestinal manifestations, showed
no additional associations. No associations were observed
with CD.
Discussion
This study firstly provides replicated confirmation
for the association of the MDR1 C3435T SNP with UC.
In addition, we have made novel observations with re-
spect to genotype-phenotype correlations, notably the
strong association of the C3435T SNP with extensive
UC. Finally, the haplotypic analyses involving C3435T
and G2677T SNPs provide further new insights into the
complexities of the contribution of the MDR1 gene; both
protective and susceptible haplotypes were identified.
Indeed, in view of the strength of the phenotypic
associations identified in the present study, it is of in-
terest to reconsider whether the positive association with
C3435T SNP seen in the study by Schwab et al26 (43%
of patients had extensive UC in that cohort) may have
been driven by this phenotype. A significant association
with extensive UC was not detected in that study, but
that may have been due to lack of statistical power in a
smaller subgroup (n  63).
Obvious care has been taken in other studies that have
examined these candidate SNPs (C3435T and G2677T/A)
by using both case-control and family-based association
designs.27,29 Croucher et al reported no association of the
C3435T SNP with UC or CD in German and British
populations.27 In the North American study, in which the
C3435T, G2677T/A, and C1236T (exon 12) SNPs were
investigated, only the G2677 allele was associated with
IBD.29 In that study, Brant et al showed that the G2677
allele (Ala893) was significantly higher in patients with
IBD compared with controls (G-allele frequency: 61.5% in
UC vs 56.5%; P  .002). Significant association was also
seen in pedigree disequilibrium transmission only for the
subset with CD.
Several factors are pertinent when considering the
apparently inconsistent results from these studies. The
descriptions of the phenotypic details of the cohorts were
lacking, and our data have now emphasized the impor-
tance of phenotypic heterogeneity. Parallels may be
drawn, in this respect, with the contribution of the
NOD2/CARD15 gene in CD.36,37 The number of sub-
jects with UC in the data sets studied was relatively
small, and these may have been underpowered to identify
a modest contribution. Moreover, the different ethnicity
and study populations may confound the overall pic-
ture,38 as also shown by the emerging data regarding
NOD2/CARD15 in European populations.
Our haplotype data provide further insight into the
contribution of the MDR1 gene in determining suscep-
tibility and disease phenotype. By combining the
2 SNPs, the haplotype 3435T/G2677 was shown to
confer an increased susceptibility to UC (P  .03; OR,
1.44; 95% CI, 1.03–1.99) whereas haplotype C3435/
2677T appeared to protect against the development of
UC (P  .002; OR, .35; 95% CI, .17–.69). The effect
was most pronounced in patients who were homozygotes
for both MDR1 3435 TT and 2677 GG genotype, but
we note that the overall number of this group was very
low (2.4%). The likelihood ratio for the haplotypic dis-
tribution in UC was also significantly different when
compared with controls (P  .0056). Thus, it appears
that these variants can alter the risk for developing UC in
a bidirectional fashion. It is particularly interesting that
the at-risk haplotype contains allelic variants associated
with reduced P-glycoprotein expression in vivo, whereas
the alleles on the protective haplotype have been associ-
ated with increased expression.
In recent years, the case for the involvement of the
MDR1 gene and P-glycoprotein 170 in determining
susceptibility in IBD has become increasingly persuasive.
It is clear, however, that the role of the MDR1 gene/P-
glycoprotein 170 in inflammation is likely to be more
complex than originally believed. Most pertinently, there
seems to be cell, tissue, and even regional organ-specific
differences in the regulation of both the function and the
expression of P-glycoprotein 170.39–43 Increasingly, in
vitro and ex vivo studies, including data from our unit
involving the HLA-B27 transgenic mice, suggest that
P-glycoprotein expression is in fact reduced in the pres-
ence of colonic inflammation.44–46 This together with
the findings by Langmann et al, showing down-regula-
tion of MDR1 (with other detoxification genes) in co-
lonic tissue of patients with UC, puts forward a compel-
ling argument for an influential role of P-glycoprotein in
determining susceptibility to UC.10 We hypothesize that
low levels of P-glycoprotein 170 expression in the gas-
trointestinal colonic epithelium increases susceptibility
and high levels are protective.
Based on our data, the C3435T but not G2677T SNP
is primarily associated with UC. This leads to the ques-
tion whether C3435T is the functional variant or in
linkage with another variant. Given that we did not
show an association with G2677T alone and that 2-locus
haplotypes were not superior in determining risk, we
clearly cannot ascribe the significant association seen
with C3435T to be secondary to linkage with
G2677T/A. The functional effect of the C3435T, a syn-
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onymous SNP that does not involve amino acid change,
nevertheless remains controversial. It remains possible
that this silent SNP can affect P-glycoprotein 170 activ-
ity/expression through, for example, effects on messenger
RNA stability or codon preference. However, it is per-
tinent that the correlation between C3435T SNP and
P-glycoprotein 170 activity/expression does not seem
consistent across ethnic groups. Studies in white popu-
lations have shown an association with MDR1 3435 TT
genotype and decreased P-glycoprotein 170 activity/ex-
pression, but the reverse is true for studies involving
Japanese populations.47–49 Therefore, we propose that the
argument that this SNP lies within tight linkage dis-
equilibrium with another unidentified causal variant re-
mains the most plausible explanation. While the hypo-
thetical model suggested by Brant et al, that C3435T
lies in linkage disequilibrium with an unknown poly-
morphism that controls expression and that the G2677T
SNP directly affects the innate P-glycoprotein 170 ac-
tivity, cannot be conclusively disproved, this seems less
likely in light of our data.
Does MDR1 have a role as a pharmacogenetic marker?
Farrell et al suggested that high P-glycoprotein 170
expression was associated with failure of medical treat-
ment in IBD.11 The study did not investigate the genetic
contribution of the MDR1 gene. The stratification to
severe disease and need for surgery in our study was
originally driven by the hypothesis that the CC genotype
(in which some studies have shown to be associated with
high expression) can predict corticosteroid resistance (se-
vere disease) and therefore surgery. This in fact was
clearly shown not to be the case in our study, with the
trend being completely reversed (MDR1 3435-TT geno-
type higher in both patients with severe disease and
requiring surgery). Recent data from the Oxford data set
in abstract form even suggest that the TT genotype of
the MDR1 3435 SNP may in fact be useful to predict
surgery in UC, in conjunction with other genetic
markers.50
Are allelic variants of the MDR1 gene implicated in
CD? Overall, we detect no significant associations with
CD and the subphenotypes according to the Vienna
classification of age at onset, disease location, and behav-
ior (data not shown). In particular, no association was
seen when we specifically considered only Crohn’s colitis
with either of the 2 SNPs. We do note, however, trends
of associations with 2-locus haplotype (haplotypes
3435T/2677T: OR, .85; P  .18; C3435/2677T: OR,
1.39; P  .19; and 3435T/G2677: OR, 1.29; P  .16).
Our CD population is smaller, and given the heteroge-
neity involved in the presentation of CD, there may be
statistical limitations in conclusively confirming or re-
futing the hypothesis of association with CD.
In conclusion, our study provides robust evidence to
support a role of the MDR1 gene in the pathogenesis of
UC. Germline MDR1 variation determines both disease
susceptibility and course in the Scottish population. The
data point to the presence of more than one functional
variant or a more haplotype-specific effect and underline
the need for parallel functional studies and haplotype
analyses.51
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